MAIA生物技术比预期的收入低,但库存却下降;其主要癌症药物正在第二阶段试验中。 MAIA Biotechnology beat earnings expectations but saw stock fall; its lead cancer drug is in Phase II trials.

以癌症治疗为重点的一家生物技术公司MAIA生物技术公司报告,季度收入为每股0.11美元,比分析师的预期值高出0.32美元。 MAIA Biotechnology, a cancer therapy-focused biotech firm, reported quarterly earnings of ($0.11) per share, beating analysts' expectations of ($0.32). 尽管如此,其股票价格下跌至约2.20美元。 Despite this, its stock price fell to about $2.20. MAIA的主要产品THIO正在第二阶段对非小细胞肺癌进行试验。 MAIA's lead product, THIO, is in Phase II trials for non-small cell lung cancer. 公司董事最近购买了股票,将内幕人士的所有权增加到公司股票的36.98%。 The company's director recently bought shares, increasing insider ownership to 36.98% of the company's stock.